Create account

Coverage dated August 19, 2026 to August 21, 2026

Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

Headline from Forbes

Newest development Aug 20, 2026 · 2 reportsModerna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

Forbes's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Developments in this update

2 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.

  1. Moderna Stock Skyrockets Over 100%

    Headline from The Daily Caller ·

  2. Newest

    Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough

    Headline from Forbes ·

2 reports not tied to one development ·

Read the reports

Reports & sources

7 articles, oldest first.

  1. BizPac Review

    Pharma stock skyrockets over 100% (opens BizPac Review)

    Published

    BizPac Review's feed description

    Shares of Moderna more than doubled Wednesday after the company and Merck announced positive results from a late-stage trial of an experimental cancer vaccine, though the companies […]

  2. The Daily Caller

    Moderna Stock Skyrockets Over 100% (opens The Daily Caller)

    Published

    The Daily Caller's feed description

    Shares of Moderna more than doubled Wednesday

  3. Inc.

    Why Moderna Stock Just Had Its Best Day Ever (opens Inc.)

    Published

    Inc.'s feed description

    Moderna shares soared almost 200 percent in a single trading session.

  4. Forbes

    Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough (opens Forbes)

    Published

    Forbes's feed description

    The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

  5. Philadelphia Inquirer

    From COVID to cancer: How Moderna’s stock jumped 177% in a day (opens Philadelphia Inquirer)

    Published

    Philadelphia Inquirer's feed description

    After demand for its COVID-19 shots plummeted, its new treatment for melanoma has reversed the Mass. company’s fortunes.

  6. Cheddar

    Moderna’s Cancer Vaccine Breakthrough Sends Stocks Soaring (opens Cheddar)

    Published

    Cheddar's feed description

    Moderna and Merck are celebrating a major milestone after their personalized mRNA cancer treatment succeeded in a late-stage trials.

Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.

Related updates

Separate coverage close to this update in time and subject.